- Home
- CGTL vs TLSI Comparison
CGTL vs TLSI Comparison
Compare CGTL & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTL
- TLSI
- Stock Information
- Founded
- CGTL 2016
- TLSI 2010
- Country
- CGTL Hong Kong
- TLSI United States
- Employees
- CGTL N/A
- TLSI N/A
- Industry
- CGTL
- TLSI Medical Specialities
- Sector
- CGTL
- TLSI Health Care
- Exchange
- CGTL NYSE
- TLSI Nasdaq
- Market Cap
- CGTL 152.2M
- TLSI 158.0M
- IPO Year
- CGTL 2024
- TLSI N/A
- Fundamental
- Price
- CGTL $5.15
- TLSI $5.77
- Analyst Decision
- CGTL
- TLSI Strong Buy
- Analyst Count
- CGTL 0
- TLSI 6
- Target Price
- CGTL N/A
- TLSI $11.75
- AVG Volume (30 Days)
- CGTL 13.0K
- TLSI 40.4K
- Earning Date
- CGTL 03-04-2025
- TLSI 03-27-2025
- Dividend Yield
- CGTL N/A
- TLSI N/A
- EPS Growth
- CGTL 35.72
- TLSI N/A
- EPS
- CGTL 0.21
- TLSI N/A
- Revenue
- CGTL $35,611,761.00
- TLSI $26,891,000.00
- Revenue This Year
- CGTL N/A
- TLSI $61.29
- Revenue Next Year
- CGTL N/A
- TLSI $53.21
- P/E Ratio
- CGTL $24.05
- TLSI N/A
- Revenue Growth
- CGTL N/A
- TLSI 67.90
- 52 Week Low
- CGTL $3.37
- TLSI $3.50
- 52 Week High
- CGTL $10.59
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- CGTL N/A
- TLSI 68.94
- Support Level
- CGTL N/A
- TLSI $5.40
- Resistance Level
- CGTL N/A
- TLSI $5.82
- Average True Range (ATR)
- CGTL 0.00
- TLSI 0.24
- MACD
- CGTL 0.00
- TLSI 0.01
- Stochastic Oscillator
- CGTL 0.00
- TLSI 89.19
About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED
Creative Global Technology Holdings Ltd Conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.